| CAS NO: | 545380-34-5 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 356.42 |
|---|---|
| Formula | C22H20N4O |
| CAS No. | 545380-34-5 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 5 mg/mL warming (14.0 mM) |
| Water:<1 mg/mL (slightly soluble or insoluble) | |
| Ethanol: <1 mg/mL (slightly soluble or insoluble) | |
| Solubility (In vivo) | 0.5% hydroxyethyl cellulose: 30 mg/mL |
| Synonyms/Chemical Name | CAY10470; CAY-10470; CAY 10470; EVP4593; EVP 4593; EVP-4593; 4-N-[2-(4-phenoxyphenyl)ethyl]quinazoline-4,6-diamine |
| In Vitro | EVP4593 inhibits TNF-a production from murine splenocytes stimulated with LPS with IC50 of 7 nM. EVP4593 (300 nM) entails a significant decrease of amplitude of store-operated currents (approximately by 60%), induced by application of 1 μM thapsigargin in Htt138Q cells, thus prevents abnormal store-operated calcium entry. |
|---|---|
| In Vivo | EVP4593 (1 mg/kg, i.p.) dose-dependently inhibits carrageenin-induced paw edema in rats. |
| Animal model | male SD rats with carrageenin induced paw edema |
| Formulation & Dosage | 0.5% hydroxypropyl cellulose; 1 mg/kg; i.p injection |
| References | [1] Tobe M, et al. Bioorg Med Chem, 2003, 11(3), 383-391. |
![]() Identification of EVP4593 in climbing assay screen with HD transgenic flies. Chem Biol. 2011 Jun 24;18(6):777-93 | ![]() SOC pathway in WT and YAC128 MSNs - Ca2+ imaging assay. Chem Biol. 2011 Jun 24;18(6):777-93 | ![]() Compounds from EVP4593 series or knockdown of TRPC1 protect YAC128 MSNs from glutamate-induced apoptosis. Chem Biol. 2011 Jun 24;18(6):777-93 |
